The FDA Has Updated Regeneron Pharmaceuticals/Sanofi's Dupixent (Dupilumab) Label In Atopic Dermatitis, Adding Efficacy, Safety Data For Patients Aged 12 Years And Older With Atopic Dermatitis With Moderate To Severe Hand And Foot Involvement
Portfolio Pulse from Benzinga Newsdesk
The FDA has updated the label for Dupixent (dupilumab), a drug co-developed by Regeneron Pharmaceuticals and Sanofi, to include efficacy and safety data for patients aged 12 and older with moderate to severe hand and foot involvement due to atopic dermatitis. This update is based on Phase 3 trial data, marking the first trial evaluating a biologic for this specific patient group. The label update has also been made in the European Union, with further regulatory submissions in progress internationally.
January 16, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron Pharmaceuticals' Dupixent label update by the FDA to include new efficacy and safety data could potentially increase the drug's usage and market share, benefiting Regeneron's revenue and market position.
The label update for Dupixent, which is co-marketed by Regeneron, is likely to enhance the drug's credibility and could lead to increased prescriptions. This is particularly significant as it addresses a difficult-to-treat population, potentially expanding the target market for Dupixent. The positive impact on Regeneron's stock is based on the expectation of increased sales and strengthened market position.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Sanofi, as a co-developer of Dupixent, stands to benefit from the FDA's label update, which may lead to expanded use in treating atopic dermatitis, potentially increasing sales and enhancing its competitive edge in the market.
Sanofi's partnership with Regeneron on Dupixent means that the updated FDA label could result in a broader patient base and increased drug sales. The new data for a specific and challenging condition could give Sanofi an advantage over competitors, likely leading to a positive short-term impact on its stock price due to anticipated revenue growth.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80